These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Experimental therapy with angiogenesis inhibitor TNP-470 on human ovarian cancer transplanted subcutaniously in nude mice].
    Author: Kong H, Jin Z, Yao M.
    Journal: Zhonghua Fu Chan Ke Za Zhi; 2002 Sep; 37(9):556-8. PubMed ID: 12411020.
    Abstract:
    OBJECTIVE: To study the effect of an angiogenesis inhibitor TNP-470 (TNP) used alone and in combination with cytoxan (CTX) in the treatment of human ovarian cancer transplanted s.c. in nude mice. METHODS: Human ovarian cancer transplanted s.c. in nude mice model was established, then divided into 5 groups: control group, vehicle group, TNP group, CTX group and TNP + CTX group, different treatments were served from day 8 after transplantation and all mice were sacrificed after 28 days. The weights of the mice and the volumes of the tumors were measured respectively during the therapy time. Moreover, microscopy was done after H&E staining. RESULTS: The growth inhibiting rates in the TNP and CTX group were 26.1% and 33.9% respectively; After combined, the rate was increased to 70.5%. There were no obvious decrease in the weight of all treated mice. CONCLUSIONS: Treatment with TNP is an potentially useful method of antitumor therapy in ovarian cancer, although the inhibition effects were not obvious in small doses. Moreover, TNP could enhance the effectiveness of antitumor drug.
    [Abstract] [Full Text] [Related] [New Search]